Equillium, a biotech firm focused on developing treatments for severe autoimmune and immuno-inflammatory disorders with unmet medical needs, has emerged as a leading player in the clinical-stage drug development space. Its flagship drug candidate, itolizumab (EQ001), is a monoclonal antibody that zeroes in on the immune checkpoint receptor CD6. Currently in Phase III clinical trials for the treatment of acute graft-versus-host disease, itolizumab has also completed a Phase Ib clinical trial for asthma and lupus nephritis. Equillium is also working on EQ101, a potential therapy for cutaneous T cell lymphoma and alopecia areata, as well as EQ102, which may help treat various gastrointestinal diseases. The company, which was previously known as Attenuate Biopharmaceuticals, was renamed Equillium in May 2017. Headquartered in La Jolla, California, Equillium has quickly become a major player in the biotech industry, despite only being incorporated in 2017.
Equillium's ticker is EQ
The company's shares trade on the TSX-V stock exchange
They are based in Toronto, Ontario
There are 11-50 employees working at Equillium
It is equilliumbio.com/home/default.aspx
Equillium is in the Services sector
Equillium is in the Advertising Agencies industry
The following five companies are Equillium's industry peers: